Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.
Merck, known as MSD outside the United States and Canada, and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, today announced the publication of research on the discovery of a novel class of candidate antimalarial agents that block multiple stages of the lifecycle of the parasite that causes the disease.
Japanese pharmaceutical firm Takeda has commenced the development of a plasma-derived therapy for COVID-19, a disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2).
Iktos, a French artificial intelligence (AI) start-up company, has joined forces with California-based research institute SRI International to accelerate discovery and development of therapies for the Wuhan coronavirus (COVID-19) and other viruses.
Akouos, Inc. (“Akouos”), a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing, today announced it has raised $105 million in an oversubscribed Series B financing.
Gilead Sciences has signed an agreement to acquire clinical-stage immuno-oncology company Forty Seven for $4.9bn.
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced a new strategic direction to accelerate the advancement of certain of its clinical development programmes.
Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform.
Japan Takeda Pharmaceutical has exercised its option to acquire PvP Biologics in a deal valued at around $330m.
Novartis has signed a collaboration and licence agreement with the Drugs for Neglected Diseases initiative (DNDi) for the joint development of LXE408 as a new oral drug for the treatment of visceral leishmaniasis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.